ariation in 96 DWP
The Average Titer and Recovery Rate of Ultra 96+ Platform The left histogram shows the average titer of mAb and Fc fusion protein production using the Ultra 96+ platform. High-titer production was accomplished with both types of antibodies in the 96 DWP at 1 mL culture volume. The graphs show an average recovery rate of 83% or more was achieved in both 1 mL culture using 96 DWP and 3 mL culture using 24 DWP. 1503
Recovery Rate (24 DWP)
Average 84%
90%
80%
70%
60%
50%
Titer Variation in 96 DWP
1 2 3 4 5 6 7 8 9 101112131415161718192021222324
Recovery Rate (24 DWP)
969
Average 84%
90%
1503
50% 50.0% 55.0% 60.0% 65.0% 70.0% 75.0% 80.0% 85.0% 90.0% 95.0% 1 3 5 7 9 11131517192123252729313335373941434547495153555759 Recovery Rate (96 DWP) Average 83% 60% 80% 1 2 3 4 5 6 7 8 9 101112131415161718192021222324 50.0% 55.0% 60.0% 65.0% 70.0% 75.0% 80.0% 85.0% 90.0% 95.0% 1 3 5 7 9 11131517192123252729313335373941434547495153555759 Recovery Rate (96 DWP) Average 83%
Need original image 70%
595
1013
969
mAb
Bispecific
Fc fusion
Control
mAb
Fc fusion
Case Study: WuXian TM uHTP Platform
The Ultra 96+ platform incorporates an ultra-high titer transient CHO expression system that significantly enhances titers and overall yields. In this case study, the Ultra 96+ platform showcases remarkable mean final yield of antibody drug molecules in 1 mL culture using 96-DWP, achieving 1.2 mg for 960 antibodies, 0.98 mg for 536 VHH-Fc, 0.55 mg for 557 Fab, and 0.3 mg for 100 His-VHH. The proteins are suitable for in vitro assays.
960 Antibodies
100 His-VHH
536 VHH-Fc
557 Flag-FABs
0 0.3 0.6 0.9 1.2 1.5 1.8 2.1
2
0.6
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
0.5
1.5
0.55 mg
0.4
1.2 mg
0.98 mg
0.3 mg
1
0.3
0.2
0.5
0.1
0
0
96 Well DWP (1 mL/well)
Learn more: Protein Sciences: uHTP Antibody Production
About WuXi Biologics
WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.
The world’s leading global single-source platform from concept to commercialization.
wuxibiologics.com | info@wuxibiologics.com
5-9-2024
Powered by FlippingBook